BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 6, 2020
View Archived Issues
From African genomes, big insights with small sample size
Read More
Commercial antibodies underwhelm for studies of PP2A
Read More
TUSC2 as a novel therapeutic target in thyroid carcinoma
Read More
Gedeon Richter patents alpha-7 nicotinic receptor positive allosteric modulators
Read More
New compounds for RNA virus infections described by CNRS and others
Read More
Rodin Therapeutics identifies new HDAC inhibitors
Read More
New Trk-A, Trk-B and Trk-C inhibitors discovered at BenevolentAI Bio
Read More
Pfizer identifies new monoglyceride lipase inhibitors
Read More
FDA clears IND application for BXCL-501 for the treatment of opioid withdrawal symptoms
Read More
Lamivudine shows promising safety and activity in p53 mutant mCRC
Read More
Phase Ib results for ficlatuzumab plus gemcitabine and nab-paclitaxel in PDAC
Read More
Interim phase I/II data for LOAd-703 plus nab-paclitaxel/gemcitabine in PDAC
Read More
Reducing stem cell senescence protects against aging
Read More
Interim phase I data on Arrowhead's ARO-APOC3 and ARO-ANG3 show improvements in lipid parameters
Read More
Phase IIb study of SAR-442168 in relapsing MS meets primary endpoint
Read More
Tonix stops enrollment in phase III PTSD study of Tonmya for futility
Read More
Antitumor activity seen with pembrolizumab in advanced anal squamous cell carcinoma trial
Read More
BiondVax reports preliminary phase II data on M-001 universal influenza vaccine candidate
Read More
Arthrosi begins phase IIa study of AR-882 for gout
Read More
Atreca and Merck & Co. collaborate to identify antibody targets in oncology
Read More